Acupuncture and Pain Counseling in Reducing Pain and Symptom Distress in Hospitalized Cancer Patients
Inclusion Criteria
- Patients admitted to University of California San Francisco (UCSF) Mission Bay Hospital or Zuckerberg San Francisco General (ZSFG) with a malignant solid tumor (e.g., breast, gastrointestinal, genito-urologic, gynecologic, head and neck, lung cancers, or lymphoma)
- Speak Cantonese, English, or Spanish
- Have an anticipated stay of >= 48 hours
- Have pain intensity of >= 4 out of 10 for worst pain in the prior 24 hours when enrolled
Exclusion Criteria
- Acupuncture contraindication
- Unstable medical condition (e.g., severe pulmonary disease, myocardial infarction)
- Admission to the psychiatric ward (e.g., for severe depression)
- Inability to consent (e.g., cognitive impairment)
- Prior involvement with the study (e.g., readmissions)
- Platelets < 50,000 uL
- Absolute neutrophil count < 500 uL
- Clostridium (C.) difficile infection
California
San Francisco
PRIMARY OBJECTIVE:
I. Determine the effectiveness of adjunctive acupuncture and of pain counseling for improving pain management.
SECONDARY OBJECTIVE:
I. Determine the extent that adjunctive acupuncture and pain counseling reduce use of opioid analgesics and side effects.
EXPLORATORY OBJECTIVE:
I. Examine stakeholder perspectives on non-pharmacologic approaches to pain management.
OUTLINE: Patients are randomized to 1 of 4 arms.
ARM I: Along with standard of care pain medication, patients undergo acupuncture over 30-60 minutes on days 1-4.
ARM II: Along with standard of care pain medication, patients undergo pain counselling over 30-60 minutes on days 1-4.
ARM III: Along with standard of care pain medication, patients undergo acupuncture and pain counseling over 30-60 minutes on days 1-4.
ARM IV: Patients receive standard of care pain medication.
After patients are discharged from the hospital, they will be followed up within 3 days and at 1 and 3 months.
Trial Phase Phase NA
Trial Type Supportive care
Lead Organization
University of California San Francisco
Principal Investigator
Maria Chao
- Primary ID 18801
- Secondary IDs NCI-2018-02204, 17-23446
- Clinicaltrials.gov ID NCT03905720